Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Eugene Science Completes Move to Larger Facility

Abstract:
New Facility Doubles Sterol Production Capacity

Eugene Science Completes Move to Larger Facility

LOS ANGELES, CA | Posted on December 4th, 2007

Eugene Science, Inc. (OTCBB: EUSI), a leader in the nutraceutical marketplace with its cholesterol lowering CholZero (CZ™) plant sterols, today announced it has completed its move into a newly constructed corporate headquarters and production facility in Seoul, Korea.

The move to the larger facility will enable the Company to double its CZ™ plant sterol production capacity to a maximum of 100 tons monthly. The higher production capacity will increase the Company's gross revenue capability to approximately $5 million per month, at a relatively minimal capital expenditure. The Company expects its increased production capacity to immediately enhance its ability to secure additional mass market orders for CZ™.

The new facility is approximately twice the size of the Company's former property and was custom built to meet Eugene Science's requirements with the Kyonggi-Do State Government subsidizing the vast majority of the construction costs as well as payments on the initial 20-year lease under local economic development programs. The Company's new facility includes 22,000 square feet of specially designed office, R&D and production space on six acres of land offering future additional build-out potential.

"The move into the new facility with higher production capacity represents a significant milestone in our growth strategy," said Seung Kwon Noh, Eugene Science's Chairman and Chief Executive Officer. "With awareness and demand for our CholZero™ product line growing, the company is well positioned for strong growth in 2008 and beyond."

The property is located in Jang-An Industrial Complex, Haw Sung City, Kyonggi-Do, about 40 miles south of Seoul and ten miles from Pyungtaek Port, an important and emerging industrial harbor servicing the capital city of Seoul.

Eugene Science expects to sell its former corporate headquarters office in Seoul with the proceeds to be used to reduce debt.

To be added to Eugene Science's investor lists, please contact Zachary Bryant at or at 818-382-9718.

####

About Eugene Science, Inc.
Based in Seoul, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart disease product, CZ™, is a patented, nanoscience-based, water-dispersible functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ™ is available in capsule form, or as a food or beverage additive. These plant sterols are approved by the U.S. FDA for health claims related to cholesterol lowering efficacy. Please visit http://www.eugene21.com .

Forward-Looking Statements: This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Eugene Science, or its representatives, have made or may make forward-looking statements, orally or in writing. The words "estimate," "project," "potential," "intended," "expect," "anticipate," "believe" and similar expressions or words are intended to identify forward-looking statements. Such forward-looking statements may be included in, but are not limited to, various filings made by Eugene Science with the United States Securities and Exchange Commission (available at www.sec.gov), press releases or oral statements made with the approval of an authorized executive officer of Eugene Science. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions. Reference is hereby made to Eugene Science's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 for information regarding those factors and conditions. Among the important factors that could cause actual results to differ materially from management's projections, estimates and expectations include, but are not limited to: changing economic influences in the nutraceutical industry; actions of third parties; the market for nutraceutical products containing Eugene Science's CZ™ ingredient, the willingness of Eugene Science's creditors to enter into restructuring and workout agreements with respect to its outstanding debt, and the availability of adequate working capital to continue Eugene Science's operations. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as of the date of this press release. Eugene Science undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

For more information, please click here

Contacts:
Investor Relations International
Zachary Bryant
Senior Vice President and Account Group Manager
818.382.9700

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Openings/New facilities/Groundbreaking/Expansion

OCSiAl expands its graphene nanotube production capacities to Europe June 17th, 2022

GLOBALFOUNDRIES Moves Corporate Headquarters to its Most Advanced Semiconductor Manufacturing Facility in New York April 27th, 2021

Oxford Instruments Plasma Technology relocates to advanced manufacturing facility: Move driven by exceptional business growth February 12th, 2021

RIT to upgrade Semiconductor and Microsystems Fabrication Laboratory through $1 million state grant: Upgrades to clean room will enhance university’s research capabilities in photonics, quantum technologies and smart systems August 16th, 2019

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project